Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma

(2017) Pier Francesco Ferrucci et al.   Oncotarget

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma

(2017) Hassan Sadozai et al.   Frontiers in Immunology

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial:

(2016) F. Stephen Hodi et al.   CANCER RESEARCH

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

(2015) P F Ferrucci et al.   BRITISH JOURNAL OF CANCER

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

(2014) Paolo A Ascierto et al.   Journal of Translational Medicine

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

(2013) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme

(2013) Maresa Altomonte et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

(2012) Riccardo Danielli et al.   Annals of the New York Academy of Sciences

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Large Randomized Study of Thymosin α 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma

(2010) Michele Maio et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010)   NEW ENGLAND JOURNAL OF MEDICINE